Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FINEARTS-HF trial of finerenone in symptomatic heart failure with left ventricular ejection fraction >=40%
MOH_2020-07-20_008872Phase 3Completed
- Sponsor
- Bayer
- Start
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of finerenone in heart failure with preserved ejection fraction (HFpEF) and heart failure (HF), sponsored by Bayer. Started Jul 2020; status: completed.
02
Drugs
finerenone
03
Conditions
heart failure with preserved ejection fraction (HFpEF)heart failure (HF)
Beyond the preview
Go deeper on MOH_2020-07-20_008872.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2020-07-20_008872.